Article Text

Download PDFPDF

331 Immunotherapy with Y90-radioembolization for metastatic colorectal cancer (iRE-C)
  1. Pashtoon Kasi1,
  2. Beau Toskich2 and
  3. Sandeep Laroia1
  1. 1University of Iowa, Iowa City, IA, USA
  2. 2Mayo Clinic, Jacksonville, FL, USA


Background For patients with microsatellite stable or mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer, immune checkpoint blockade does not work. Strategies are being devised where immunotherapy is being combined with other novel agents or radiotherapy to enhance PD-L1 expression, alter the tumor microenvironment (turning ‘cold’ tumors ‘hot’) and/or release neoantigens to enhance efficacy of immune checkpoint blockade. We chose Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy given pre- and post-Y90-RE as a treatment strategy to be examined as part of a clinical trial for those patients with metastatic colorectal cancer who have liver-predominant or liver-only metastases.

Methods This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy (durvalumab - 750 mg) in subjects with liver-predominant, metastatic colorectal cancer (mCRC), which is mismatch repair proficient/microsatellite stable (pMMR/MSS). As noted on, the purpose of this clinical trial is to find out more about the side effects of immunotherapy with a form of radiation treatment for the cancer in the liver called Yttrium-90 RadioEmbolization (Y90-RE). An immunotherapy drug, durvalumab, will be given intravenously every 2 weeks. We are studying what doses of durvalumab are safe for people in combination with this form of radiation treatment. Patients in this study will receive durvalumab, which is experimental and not approved by the U.S. Food and Drug Administration (FDA) for metastatic colorectal cancer. Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver.The number of doses of the immunotherapy drug (range: 2 to 5) will depend on the cohort patients are assigned to. There is no placebo. Everyone on the study is treated with immunotherapy alongside the Y90-RadioEmbolization (table 1). Primary objective is to look at safety and feasibility of this approach. Once the recommended phase-2 dose is determined through an acceleration titration design, a total of 18 patients are being planned to be treated on this study at the University of Iowa Holden Comprehensive Cancer Center. The study has strong correlational components from a tumor microenvironment (pre- and post-biopsies) as well as ‘liquid biopsies’ - circulating tumor DNA (ctDNA) testing already integrated into the protocol. This would provide an opportunity to understand better the changes to the tumor microenvironment from such an approach in addition to understanding mechanisms of immune evasion/resistance.

Abstract 331 Table 1

Dose escalation cohort of durvalumab.

Results N/A

Conclusions N/A

Trial Registration NCT04108481


  1. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine 2015; 372:2509–20.

  2. Chew V, Lee YH, Pan L, et al. Immune activation underlies a sustained clinical response to yttrium-90 radioembolisation in hepatocellular carcinoma. Gut, 2018 Feb 13; doi: 10.1136/gutjnl-2017-315485

  3. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncology 2015; 1(9):1325.

  4. den Brok MH, Stutmuller RP, van der Voort R, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004; 64:4024-9.

  5. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancr Res 2009; 15(17):5379–88.

  6. Hazel Gav, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized Phase II Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2016; 34:1723–31.

  7. Hickey R, Lewandowski RJ, Prudhomme T, et al. Y90 radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531- patient multicenter study. J Nucl Med 2016; 57(5): 665–71.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.